Immunotherapies Discussed for Melanoma
Source: Targeted Oncology, April 2023
What data from the CheckMate 067 (NCT01844505), KEYNOTE-006 (NCT01866319), and RELATIVITY-047 (NCT03470922) trials would influence your choice of immunotherapy for metastatic melanoma?
MICHAEL B. ATKINS: Does anybody think that investigator-assessed versus blinded independent central review made a difference [in the overall response rates reported in these trials]?
LISA BADDI, MD: In most studies there’s usually a difference between the investigator’s [more] optimistic assessment and the independent assessment.